Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Leukemia

Inotuzumab Ozogamicin for Relapsed Or Refractory Acute Lymphoblastic Leukemia (20121582)
An Open-Label, Randomized Phase 3 Study Of Inotuzumab Ozogamicin Compared To A Defined Investigator's Choice In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status Conditions Phase Study ID
Recruiting Acute Lymphoblastic Leukemia Phase III 20121582
NCT01564784
Summary

This study will compare the efficacy, in terms of complete responses and overall survival, of inotuzumab ozogamicin versus investigator's choice of chemotherapy.


Investigator
Dr. Ryan Cassaday
Location    
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)
  • CD22 expression
  • Adequate liver and renal functions

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)
  • Isolated extramedullary disease
  • Active Central Nervous System [CNS] disease

Other exclusion criteria may apply.

Last Updated
October 14, 2014
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.